Non–Small Cell Lung Cancer Clinical Care

Gain perspectives from experts on various policy issues and therapeutic areas through our Insights series that engages multiple managed care stakeholders in video interviews.

The Changing Landscape of NSCLC Clinical Care
May 22, 2019 – 
Benjamin Levy, MD, and Anne Tsao, MD, consider the changing treatment landscape of NSCLC clinical care.
ALK Inhibitors and BRAF/MEK Inhibitors for NSCLC
May 15, 2019 – 
Key opinion leaders consider the evolving clinical care of patients with non–small cell lung cancer.
The Impact of EGFR TKI on Nonsquamous NSCLC
May 15, 2019 – 
A discussion on the use of EGFR TKIs in treating nonsquamous NSCLC with driver mutation.
 
Ramucirumab for Relapsed-Refractory Metastatic NSCLC
May 08, 2019 – 
Expert physicians discuss the patient selection and sequencing strategy for ramucirumab and consider whether the KEYNOTE-189 trial has changed the treatment strategy.
The REVEL Trial and Subanalysis
May 08, 2019 – 
A discussion on the REVEL trial and subanalysis and ramucirumab treatment factors for relapsed and refractory nondriver metastatic non–small cell lung cancer.
 
Pembrolizumab for Relapsed/Refractory Metastatic NSCLC
May 01, 2019 – 
Oncologists discuss the role of pembrolizumab in treating relapsed/refractory nondriver metastatic NSCLC.
Combination I-O Treatment Factors & Preference
May 01, 2019 – 
Key opinion leaders discuss the immuno-combination treatment factors for patients with metastatic NSCLC.
Metastatic NSCLC I-O Combination Therapies
April 24, 2019 – 
A discussion on the available immuno-combination therapies for patients with metastatic non–small lung cancer, with special consideration to the CheckMate 227, IMpower150 and -131 studies.
NSCLC Treatment: Low PD-L1 Status and Chemotherapy
April 24, 2019 – 
Oncologists consider the management of patients with low PD-L1 status and the role of chemotherapy in treating patients with nondriver non–small cell lung cancer.
 
Nondriver NSCLC Trials: KEYNOTE-189, -407, -024
April 17, 2019 – 
A discussion on the design, results, and practical implication of KEYNOTE-189, -407, and -024 trials.
 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.